docetaxel anhydrous has been researched along with erdafitinib in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (erdafitinib) | Trials (erdafitinib) | Recent Studies (post-2010) (erdafitinib) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 88 | 12 | 86 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | erdafitinib (IC50) |
|---|---|---|---|
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | 0.2198 | |
| Fibroblast growth factor receptor 2 | Homo sapiens (human) | 0.0037 | |
| Fibroblast growth factor receptor 4 | Homo sapiens (human) | 0.0073 | |
| Fibroblast growth factor receptor 3 | Homo sapiens (human) | 0.0144 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.6886 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akapame, S; Banek, S; Burgess, EF; Deprince, K; Guadalupi, V; Houede, N; Huddart, RA; Kean, Y; Ku, JH; Loriot, Y; Matsubara, N; Mukhopadhyay, S; Park, SH; Siefker-Radtke, AO; Stone, NL; Tran, B; Triantos, S; Valderrama, BP | 1 |
1 trial(s) available for docetaxel anhydrous and erdafitinib
| Article | Year |
|---|---|
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Docetaxel; Humans; Immune Checkpoint Inhibitors; Receptors, Fibroblast Growth Factor; Urinary Bladder Neoplasms | 2023 |